respiratory
Pulmonary fibrosis

New details emerge on pulmonary adverse effects of low-dose MTX

A major trial has provided more details about the risk of lung injury with low dose methotrexate (MTX) and in particular for MTX-related pneumonitis. One of the largest studies ever of low dose methotrexate use – involving 2,391 people randomised to receive the drug – showed a rate of severe pulmonary adverse events of 0.5%, ...

Already a member?

Login to keep reading.


OR
© 2020 the limbic